Immune therapies in acute myeloid leukemia: A focus on monoclonal antibodies and immune checkpoint inhibitors

Current Opinion in Hematology

Volumn 25, Issue 2, 2018, Pages 136-145

  Assi, Rita ^a   Kantarjian, Hagop ^a   Ravandi, Farhad ^a   Daver, Naval ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

bi specific antibodies; immune checkpoint inhibitors; immunotherapy; monoclonal antibodies

Indexed keywords

AMG 330; ATEZOLIZUMAB; AVELUMAB; AZACITIDINE; BUSULFAN; CD123 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DAUNORUBICIN; DECITABINE; DIPHTHERIA TOXIN INTERLEUKIN 3; DURVALUMAB; FLOTETUZUMAB; GEMTUZUMAB OZOGAMICIN; HYDROXYUREA; IDARUBICIN; IMGN 779; IPILIMUMAB; JNJ 63709178; LIRILUMAB; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; NIVOLUMAB; NJ 63709178; PEMBROLIZUMAB; PIDILIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; TALACOTUZUMAB; UNCLASSIFIED DRUG; VADASTUXIMAB TALIRINE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; IMMUNOTOXIN; PDCD1 PROTEIN, HUMAN;

ABDOMINAL PAIN; ACUTE MYELOID LEUKEMIA; BONE MARROW; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CAPILLARY LEAK SYNDROME; CARDIOVASCULAR MORTALITY; CD8+ T LYMPHOCYTE; CYTOGENETICS; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; EPIGENETICS; EPIGLOTTITIS; EVENT FREE SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTOXICITY; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LYMPHOCYTIC INFILTRATION; META ANALYSIS (TOPIC); NEPHRITIS; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; RECURRENCE FREE SURVIVAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; THROMBOCYTOPENIA; VEIN OCCLUSION; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; IMMUNOTHERAPY; PATHOLOGY; PROCEDURES;

ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; IMMUNOTOXINS; LEUKEMIA, MYELOID, ACUTE; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85042435982     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000401     Document Type: Review

References (78)

1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med 2015; 373:1136-1152.
2. Yates JW, Wallace HJ, Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep 1973; 57:485-488.
3. Estey E. Why is progress in acute myeloid leukemia so slow Semin Hematol 2015; 52:243-248.
4. Medinger M, Lengerke C, Passweg J. Novel prognostic and therapeutic mutations in acute myeloid leukemia. Cancer Genomics Proteomics 2016; 13:317-329.
5. Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 2017; 376: 836-847.
6. Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 2014; 15:986-996.
7. Castaigne S, Pautas C, TerréC, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study. Lancet 2012; 379:1508-1516.
8. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell 2015; 161:205-214.
9. Majeti R. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene 2011; 30:1009-1019.
10. Saito Y, Kitamura H, Hijikata A, et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med 2010; 2:; 17ra19.
11. Matthews DC. Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome. Leukemia 1998; 12(Suppl 1):S33-S36.
12. Jilani I, Estey E, Huh Y, et al. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol 2002; 118:560-566.
13. Anguille S, Van Tendeloo VF, Berneman ZN. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia 2012; 26:2186-2196.
14. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19:3244-3254.
15. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7:1490-1496.
16. Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005; 104:1442-1452.
17. Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013; 121:4854-4860.
18. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011; 29:369-377.
19. Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012; 30:3924-3931.
20. Loke J, Khan JN, Wilson JS, et al. Mylotarg has potent antileukaemic effect: A systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia. Ann Hematol 2015; 94:361-373.
21. Amadori S, Suciu S, Selleslag D, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. J Clin Oncol 2016; 34:972-979.
22. Taksin AL, Legrand O, Raffoux E, et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: A prospective study of the alfa group. Leukemia 2007; 21:66-71.
23. McCombs JR, Owen SC. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. AAPS J 2015; 17:339-351.
24. Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 2005; 19:176-182.
25. Nguyen DH, Ball ED, Varki A. Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs. Exp Hematol 2006; 34:728-735.
26. Ehninger A, Kramer M, Röllig C, et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J 2014; 4:e218.
27. Kung Sutherland MS, Walter RB, Jeffrey SC, et al. SGN-CD33A: A novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 2013; 122:1455-1463.
28. Bixby DL, Stein A, Fathi AT, et al. Vadastuximab talirine monotherapy in older patients with treatment naive CD33-positive acute myeloid leukemia (AML). Blood 2016; 128:590.
29. Vasu S, He S, Cheney C, et al. Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts. Blood 2016; 127:2879-2889.
30. Fathi AT, Erba HP, Lancet JE, et al. Vadastuximab Talirine Plus Hypomethylating Agents: A Well To-Lerated Regimen With High Remission Rate In Frontline Older Patients With Acute Myeloid Leukemia (AML). Blood 2016; 128:591.
31. Erba HP, Levy M, Vasu S, et al. A Phase 1b Study of Vadastuximab Talirine in Combination with 73 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood 2016; 128:211.
32. Krystal WM, Walker R, Fishkin N, et al. IMGN779, a CD33-targeted antibodydrug conjugate (ADC) with a novel DNA alkylating effector molecule, induces DNA damage, cell cycle arrest, and apoptosis in AML cells. Blood 2015; 126:1366.
33. Whiteman KR, Noordhuis P, Walker R, et al. The antibody-drug conjugate (ADC) IMGN779 is highly active in vitro and in vivo against acute myeloid leukemia (AML) with FLT3-ITD mutations. Blood 2014; 124:2321.
34. Testa U, Pelosi E, Frankel A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res 2014; 2:4.
35. Mardiros A, Dos Santos C, McDonald T, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood 2013; 122:3138-3148.
36. Arai N, Saito B, Abe M, et al. Immunohistochemical expression of CD123 is associated with an inferior clinical outcome in acute myeloid leukemia. ASH 2016; 128:2887.
37. Frankel AE, Ramage J, Kiser M, et al. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor. Protein Eng 2000; 13:575-581.
38. Sweet K, Pemmaraju N, Lane A, et al. Lead-in stage results of a pivotal trial of SL-401, an interleukin-3 receptor (IL-3R) targeting biologic, in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) or acute myeloid leukemia (AML). Blood 2015; 126:3795.
39. Pemmaraju NLA, Sweet K, et al. Results from phase 2 trial ongoing expansion stage of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood 2016; 128:342.
40. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009; 69:4941-4944.
41. Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today 2015; 20:838-847.
42. Krupka C, Kufer P, Kischel R, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 2014; 123:356-365.
43. Laszlo GS, Gudgeon CJ, Harrington KH, et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood 2014; 123:554-561.
44. Desrichard A, Snyder A, Chan TA. Cancer neoantigens and applications for immunotherapy. Clin Cancer Res 2016; 22:807-812.
45. Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity 2013; 39:1-10.
46. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271:1734-1736.
47. Linsley PS, Greene JL, Brady W, et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994; 1:793-801.
48. Vidriales MB, Orfao A, López-Berges MC, et al. Lymphoid subsets in acute myeloid leukemias: increased number of cells with NK phenotype and normal T-cell distribution. Ann Hematol 1993; 67:217-222.
49. Andorsky DJ, Yamada RE, Said J, et al. Programmed death ligand 1 is expressed by nonhodgkin lymphomas and inhibits the activity of tumorassociated T cells. Clin Cancer Res 2011; 17:4232-4244.
50. Daver N, Basu S, Garcia-Manero G, et al. Defining the immune checkpoint landscape in patients with acute myeloid leukemia. Blood 2016; 128:2900.
51. Van den Hove LE, Vandenberghe P, Van Gool SW, et al. Peripheral blood lymphocyte subset shifts in patients with untreated hematological tumors: evidence for systemic activation of the T cell compartment. Leuk Res 1998; 22:175-184.
52. Wendelbo Ø, Nesthus I, Sjo M, et al. Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia. Cancer Immunol Immunother 2004; 53:740-747.
53. Yang H, Bueso-Ramos C, DiNardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 2014; 28:1280-1288.
54. Whiteway A, Corbett T, Anderson R, et al. Expression of co-stimulatory molecules on acute myeloid leukaemia blasts may effect duration of first remission. Br J Haematol 2003; 120:442-451.
55. Graf M, Reif S, Hecht K, et al. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML). Ann Hematol 2005; 84:287-297.
56. Chen X, Liu S, Wang L, et al. Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia. Cancer Biol Ther 2008; 7:622-627.
57. Schnorfeil FM, Lichtenegger FS, Emmerig K, et al. T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. J Hematol Oncol 2015; 8:93.
58. Fevery S, Billiau AD, Sprangers B, et al. CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graftversus-host disease. Leukemia 2007; 21:1451-1459.
59. Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 2009; 114:1545-1552.
60. Koestner W, Hapke M, Herbst J, et al. PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8 T cells. Blood 2011; 117:1030-1041.
61. Zhou Q, Munger ME, Veenstra RG, et al. Coexpression of Tim-3 and PD-1 identifies a CD8 T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011; 117:4501-4510.
62. Zhou Q, Munger ME, Highfill SL, et al. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood 2010; 116:2484-2493.
63. Boddu P, Kantarjian H, Garcia-Manero G, et al. The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma 2017; 1-13. [Epub ahead of print]
64. Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14:3044-3051.
65. Davids MS, Kim HT, Bachireddy P, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med 2016; 375:143-153.
66. Stahl M, Kohrman N, Gore SD, et al. Epigenetics in cancer: A hematological perspective. PLoS Genet 2016; 12:e1006193.
67. Héninger E, Krueger TE, Lang JM. Augmenting antitumor immune responses with epigenetic modifying agents. Front Immunol 2015; 6:29.
68. Baylin SB, Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011; 11:726-734.
69. Wrangle J, Wang W, Koch A, et al. Alterations of immune response of nonsmall cell lung cancer with azacytidine. Oncotarget 2013; 4:2067-2079.
70. Zhang N, Bevan MJ. CD8() T cells: foot soldiers of the immune system. Immunity 2011; 35:161-168.
71. Daver N, Basu S, Garcia-Manero G, et al. Phase IB/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML. J Clin Oncol 2017; 35:7026.
72. Daver N, Garcia-Manero G, Cortes JE, et al. Phase IB/II study of lirilumab with azacytidine (AZA) in relapsed AML. J Clin Oncol 2017; 35:e18505.
73. Vereecque R, Saudemont A, Quesnel B. Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells. Leukemia 2004; 18:1223-1230.
74. Krupka C, Kufer P, Kischel R, et al. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Leukemia 2016; 30:484-491.
75. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361:1058-1066.
76. Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368:2059-2074.
77. Zhou Q, Bucher C, Munger ME, et al. Depletion of endogenous tumorassociated regulatory T cells improves the efficacy of adoptive cytotoxic Tcell immunotherapy in murine acute myeloid leukemia. Blood 2009; 114:3793-3802.
78. Curran E, Corrales L, Kline J. Targeting the innate immune system as immunotherapy for acute myeloid leukemia. Front Oncol 2015; 5:83.